Proton pump inhibitors in the treatment of gastroduodenal ulcer bleeding: optimization of drug therapy methods

Abstract

Currently, peptic ulcer disease remains the most common disease of the digestive system. Ulcerative bleeding is a terrible complication. The main condition for the successful conservative treatment of gastrointestinal bleeding that occurs against the background of acid-dependent diseases is adequate acid-reducing therapy. We conducted a study comparing the different modes of administration of proton pump blockers. To this end, three groups of the study were formed: the first group: the drug Rabeprazole was obtained as an antisecretory therapy. The dosing regimen consisted in the introduction of a bolus of 80 mg, then a constant infusion of the drug at a rate of 8 mg per hour for the first 72 hours, after which the transfer to the oral form of 20 mg ×2 times a day; the second group: received the drug rabeprazole intravenously in a dosage of 40 mg 2 times a day; the third group: received the drug rabeprazole intravenously in a dosage of 20 mg 2 times a day for the first 72 hours, then transfer to the oral form of 20 mg ×twice a day. The use of PPIs in various dosages in the study groups significantly reduced the risk of bleeding relapses and deaths. We have shown that the use of PPIs in reduced dosages is also an effective method of treating patients with ulcerative gastroduodenal bleeding.